InnoCare Pharma Ltd.SSE: 688428

Announcement on Voluntary Disclosure of Soficitinib (ICP-332) Achieving the Primary Endpoint in a Phase II Study for the Treatment of Non-segmental Vitiligo

· Issued by InnoCare Pharma Ltd. via Shanghai Stock Exchange

Filed with SSE ·

On 6ix: 6ix.com/news/innocare-pharma-limitedannouncement-on-voluntary-disclosure-of-soficitinib-icp-332-achieving-the-primary-endpoint-in-a-phase-ii-study-for-the-treatment-of-non-segmental-vitiligo

Announcement on Voluntary Disclosure of Soficitinib (ICP-332) Achieving the Primary Endpoint in a Phase II Study for the Treatment of Non-segmental Vitiligo

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

InnoCare Pharma Ltd. on 6ix

Earlier from InnoCare Pharma

Later from InnoCare Pharma

All InnoCare Pharma news releases